

Papua NG Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Papua NG			
2. Grant number: 17-PNG-12c-X / /			
3. Date of Decision Letter: 16 December 2016			
4. Date of the Partnership Framework Agreement: 29 November 2013			
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID			
8. Programme duration¹: 2013 -2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2013-2016	2017	Total ²
Programme Budget (US\$)	8,114,239 ³	903,000	9,017,239
10. Vaccine introduction grant (in US\$): Not applicable.			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2013-2016	2017	
Number of Pneumococcal vaccines doses		225,800	
Annual Amounts (US\$)	8,114,239 ⁵	903,000	

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.															
13. Self-procurement: Not applicable.															
<p>14. Co-financing obligations: Reference code: 17-PNG-12c-X-C According to the co-financing policy, the Country falls within the group Accelerated transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <tr> <td>Type of supplies to be purchased with Country funds in each year</td> <td>2017</td> </tr> <tr> <td>Number of vaccine doses</td> <td>208,600</td> </tr> <tr> <td>Number of AD syringes</td> <td></td> </tr> <tr> <td>Number of re-constitution syringes</td> <td></td> </tr> <tr> <td>Number of safety boxes</td> <td></td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>688,371</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>721,500</td> </tr> </table>		Type of supplies to be purchased with Country funds in each year	2017	Number of vaccine doses	208,600	Number of AD syringes		Number of re-constitution syringes		Number of safety boxes		Value of vaccine doses (US\$)	688,371	Total co-financing payments (US\$) (including freight)	721,500
Type of supplies to be purchased with Country funds in each year	2017														
Number of vaccine doses	208,600														
Number of AD syringes															
Number of re-constitution syringes															
Number of safety boxes															
Value of vaccine doses (US\$)	688,371														
Total co-financing payments (US\$) (including freight)	721,500														
15. Operational support for campaigns: Not applicable															
16. Additional reporting requirements: Not applicable															
Reports and other information	Due dates														
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May														
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat														
17. Financial clarifications: Not applicable															
18. Other conditions: Not applicable															

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

16 December 2016